Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18472944 | 0.92 | ESR2 (0.46) | LMNAHTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL19621827 | 0.92 | ESR2 (0.46) | LMNAHTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL24799881 | 0.87 | ESR2 (0.41) | LMNAHTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL19624016 | 0.84 | SPHK1 (0.47) | SLC6A3 | |
| SCHEMBL18472839 | 0.79 | SLC6A2 (0.38) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL20614364 | 0.76 | HTR2A (0.37) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL19311575 | 0.76 | HTR2A (0.37) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL18511247 | 0.76 | HTR2A (0.44) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL1405569 | 0.75 | ESR2 (0.50) | LMNAHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL15451574 | 0.74 | ESR2 (0.41) | LMNASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017102053-A2 | CINNAMIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| US-7732021-B2 | Liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20080277623-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080277623-A1 | Liquid Crystalline Medium | CHRM1, NEFM, CCNT1 | LMNA 80/4885HTR2A 3303/4885HTR2C 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.